Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
← catalyst calendarNCT06846996 · readout in 346 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
260estimated
Sites
40
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-27 | actual | When the study began enrolling |
| Primary completion | 2027-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- HER2-positive Gastric Cancer
- HER2-positive Gastroesophageal Junction
Intervention
- Drug: Trastuzumab deruxtecan (T-DXd)
Primary outcome
what the primary-completion date above is the date OFReal-world Time to Treatment Failure (rwTTF)
measured T-DXd treatment initiation date (index date) to date of treatment discontinuation due to disease progression, physician decision, adverse events or death, whichever occurs first, up to approximately 2 years
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed